Understanding Novel Oncogenic Regulators in Breast Cancer with the Lionheart FX

7 September 2018

Scientists at Stony Brook University, New York, have discovered that the previously known antiviral protein BST2, also known as tetherin or CD371, functions as an oncogenic driver in breast cancer-promoting cell adhesion, growth, migration and invasion of tumor cells. In this video, discover how the automated imaging system of BioTek's LionheartTM FX platform has enabled the group to unearth many of the structure-function relationships of BST2 in cancer, whilst eliminating investigator bias and enabling highly accurate acquisition of kinetic data. Read our article for more information on research in the Okeoma lab.